BOOK
Pediatric Infectious Disease: Part II, An Issue of Infectious Disease Clinics of North America, E-Book
(2016)
Additional Information
Book Details
Abstract
This issue of Infectious Disease Clinics of North America, Guest Edited by Mary Anne Jackson, MD and Angela Myers, MD, is Part II of a 2-part issue devoted to Pediatric Infectious Diseases. Drs. Jackson and Myers have assembled a group of expert authors to review the following topics: Measles 50 Years After Initiation of MMR Vaccine; Pertussis in the Era of New Strains; Promoting Vaccine Confidence; The Changing Epidemiology of Meningococcal Infection; Prevention of Influenza in Children; Rabies - Rare Human Infection, Common Questions; The Expanded Impact of Human Papillomavirus Vaccine; The Challenge of Global Poliomyelitis Eradication; The Eradication of Pediatric Rotavirus Infection; Approach to Immunization for the Traveling Child; and Status of Pneumococcal Infection in the US in the conjugate vaccine era.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Pediatric Infectious\rDisease: Part II | i | ||
| Copyright | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Preface: Pediatric Infectious Diseases, Part 2 | vii | ||
| Prevention of Influenza in Children | vii | ||
| Rotavirus Infection: A Disease of the Past? | vii | ||
| Rabies: Rare Human Infection – Common Questions | vii | ||
| The Challenge of Global Poliomyelitis Eradication | viii | ||
| The Changing Epidemiology of Meningococcal Disease | viii | ||
| Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine | viii | ||
| Pertussis in the Era of New Strains of Bordetella pertussis | viii | ||
| The Expanded Impact of Human Papillomavirus Vaccine | ix | ||
| Measles 50 Years After Use of Measles Vaccine | ix | ||
| Approach to Immunization for the Traveling Child | ix | ||
| Promoting Vaccine Confidence | ix | ||
| INFECTIOUS DISEASE CLINICS\rOF NORTH AMERICA | xi | ||
| FORTHCOMING ISSUES | xi | ||
| March 2016 | xi | ||
| June 2016 | xi | ||
| September 2016 | xi | ||
| RECENT ISSUES | xi | ||
| September 2015 | xi | ||
| June 2015 | xi | ||
| March 2015 | xi | ||
| Preface: Pediatric Infectious Diseases, Part 2 | xiii | ||
| Prevention of Influenza in Children | 597 | ||
| Key points | 597 | ||
| INTRODUCTION | 597 | ||
| INCIDENCE AND MORTALITY RATES | 598 | ||
| PATIENT HISTORY | 598 | ||
| PHYSICAL EXAMINATION | 599 | ||
| ADDITIONAL TESTING AND IMAGING | 599 | ||
| TREATMENT AND CHEMOPROPHYLAXIS | 602 | ||
| CLINICAL OUTCOMES AND COMPLICATIONS | 604 | ||
| PREVENTION | 608 | ||
| Influenza Vaccine | 608 | ||
| Chemoprophylaxis | 612 | ||
| SUMMARY | 612 | ||
| REFERENCES | 612 | ||
| Rotavirus Infection | 617 | ||
| Key points | 617 | ||
| ROTAVIRUS DISEASE BURDEN | 617 | ||
| CLINICAL ASPECTS OF ROTAVIRUS DISEASE | 618 | ||
| EPIDEMIOLOGY OF ROTAVIRUS DISEASE | 619 | ||
| PROSPECTS OF ERADICATION OF ROTAVIRUS DISEASE | 619 | ||
| Prevention of Rotavirus Infection Through Vaccination | 619 | ||
| Rotavirus Strain Diversity | 620 | ||
| Rotavirus Vaccine Development Strategies | 621 | ||
| Results of Clinical Trials of Rotavirus Vaccines | 623 | ||
| AVAILABLE ROTAVIRUS VACCINES | 624 | ||
| Recommendations for Use of the Licensed Rotavirus Vaccines | 624 | ||
| Evaluation of the Safety Profile of Rotavirus Vaccine After Licensure | 625 | ||
| Rotavirus Vaccine Coverage | 625 | ||
| United States | 625 | ||
| Global | 625 | ||
| Rotavirus Surveillance to Monitor Vaccine Programs | 626 | ||
| United States surveillance programs | 626 | ||
| World Health Organization surveillance programs | 626 | ||
| Evaluation of the Effect of Rotavirus Vaccine Programs | 626 | ||
| The Effectiveness of Rotavirus Vaccination in the Prevention of Rotavirus Disease | 626 | ||
| Duration of Immunity | 627 | ||
| The Impact of Rotavirus Vaccination on the Health Burden of Rotavirus Disease | 627 | ||
| Herd Immunity After Rotavirus Vaccination | 627 | ||
| Changing Epidemiology and Seasonality of Rotavirus Disease After Vaccine Introduction | 628 | ||
| Effect of Vaccination on Rotavirus Strain Circulation and Emergence | 628 | ||
| CHALLENGES AND OPPORTUNITIES | 630 | ||
| Low Vaccine Coverage | 630 | ||
| Need for Large Field Efficacy Trials and After-Licensure Surveillance for New Vaccine Candidates | 630 | ||
| Diminished Efficacy in High-Burden Low-Income Settings | 630 | ||
| Need for Long-Term Surveillance to Monitor the Effects of Vaccination Programs | 631 | ||
| Research Needs | 631 | ||
| REFERENCES | 631 | ||
| Rabies | 637 | ||
| Key points | 637 | ||
| NATURAL HISTORY | 637 | ||
| DIAGNOSIS | 639 | ||
| PROGNOSIS | 641 | ||
| MANAGEMENT | 643 | ||
| COMPLICATIONS | 644 | ||
| EVIDENCE | 644 | ||
| CONTROVERSIES | 645 | ||
| REFERENCES | 646 | ||
| The Challenge of Global Poliomyelitis Eradication | 651 | ||
| Key points | 651 | ||
| INTRODUCTION | 652 | ||
| POLIO AS A CANDIDATE FOR ERADICATION | 652 | ||
| CLINICAL ASPECTS OF POLIO | 652 | ||
| EPIDEMIOLOGY OF POLIO | 653 | ||
| PROGRESS TOWARD GLOBAL ERADICATION OF POLIO | 655 | ||
| ERADICATION STRATEGIES | 655 | ||
| AVAILABLE VACCINES | 656 | ||
| Oral Poliovirus Vaccine | 656 | ||
| Risks of Oral Poliovirus Vaccine | 657 | ||
| Vaccine-associated paralytic polio | 657 | ||
| Circulating vaccine-derived poliovirus | 657 | ||
| Inactivated Poliovirus Vaccine | 657 | ||
| Concerns raised with Inactivated Poliovirus Vaccine | 658 | ||
| USING ORAL AND INACTIVATED POLIOVIRUS VACCINES TOGETHER | 658 | ||
| ENDGAME STRATEGY AND TIMELINE | 659 | ||
| CHALLENGES AND OPPORTUNITIES | 659 | ||
| POSTERADICATION RISKS AND MITIGATION | 660 | ||
| RESEARCH NEEDS | 662 | ||
| ROLE OF NORTH AMERICAN PHYSICIANS | 662 | ||
| REFERENCES | 662 | ||
| The Changing Epidemiology of Meningococcal Disease | 667 | ||
| Key points | 667 | ||
| INTRODUCTION | 667 | ||
| THE DISEASE AS CANDIDATE FOR ERADICATION | 668 | ||
| CLINICAL ASPECTS | 669 | ||
| EPIDEMIOLOGY | 670 | ||
| AVAILABLE VACCINES | 672 | ||
| IMPACT OF VACCINATION ON DISEASE CONTROL | 673 | ||
| CHALLENGES AND OPPORTUNITIES | 674 | ||
| RESEARCH NEEDS | 674 | ||
| REFERENCES | 675 | ||
| Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine | 679 | ||
| Key points | 679 | ||
| EPIDEMIOLOGY | 680 | ||
| PNEUMOCOCCAL DISEASE IN CHILDREN WITH COMORBID CONDITIONS | 684 | ||
| LABORATORY DIAGNOSIS | 685 | ||
| TREATMENT | 687 | ||
| Pneumococcal Meningitis | 688 | ||
| Pneumococcal Pneumonia | 689 | ||
| PREVENTION | 690 | ||
| SUMMARY | 693 | ||
| REFERENCES | 693 | ||
| Pertussis in the Era of New Strains of Bordetella pertussis | 699 | ||
| Key points | 699 | ||
| ETIOLOGY, TRANSMISSION, AND VIRULENCE | 699 | ||
| EPIDEMIOLOGY | 700 | ||
| Role of Waning Immunity in Current Epidemiology | 702 | ||
| Role of Strain Adaptation in Current Epidemiology | 703 | ||
| Fimbriae | 703 | ||
| Pertussis toxin | 704 | ||
| Pertactin | 704 | ||
| CLINICAL FEATURES | 705 | ||
| DIAGNOSIS | 706 | ||
| TREATMENT | 707 | ||
| PREVENTION STRATEGIES | 708 | ||
| REFERENCES | 710 | ||
| The Expanded Impact of Human Papillomavirus Vaccine | 715 | ||
| Key points | 715 | ||
| INTRODUCTION | 715 | ||
| ETIOLOGY | 716 | ||
| INCIDENCE AND PREVALENCE | 716 | ||
| TRANSMISSION | 716 | ||
| CLINICAL PRESENTATION | 717 | ||
| Asymptomatic | 717 | ||
| Warts | 717 | ||
| Cancer | 717 | ||
| Special Populations | 718 | ||
| DIAGNOSIS | 718 | ||
| Molecular Testing | 718 | ||
| Serology | 718 | ||
| TREATMENT/COMPLICATIONS | 718 | ||
| PROSPECTS OF ERADICATION/ERADICATION STRATEGIES | 718 | ||
| AVAILABLE VACCINES | 719 | ||
| Human Papilloma Virus Vaccines Advisory Committee on Immunization Practices Indications | 720 | ||
| Routine use | 720 | ||
| Catch-up ages | 721 | ||
| Permissive use | 721 | ||
| Vaccine Safety | 721 | ||
| Vaccine Efficacy | 721 | ||
| Vaccine Precautions and Contraindications | 722 | ||
| RESEARCH NEEDS | 722 | ||
| REFERENCES | 723 | ||
| Measles 50 Years After Use of Measles Vaccine | 725 | ||
| Key points | 725 | ||
| INTRODUCTION | 725 | ||
| MEASLES HISTORICAL ASPECTS AND VIROLOGY | 726 | ||
| MEASLES PATHOGENESIS | 726 | ||
| DISEASE DESCRIPTION | 728 | ||
| PREVACCINE MEASLES DISEASE BURDEN | 729 | ||
| MEASLES EPIDEMIOLOGY | 729 | ||
| PREVENTION BY VACCINATION | 734 | ||
| Contraindications and Precautions | 735 | ||
| Safety and Efficacy/Effectiveness | 736 | ||
| PATIENT HISTORY | 736 | ||
| DIFFERENTIAL DIAGNOSIS | 736 | ||
| DIAGNOSTIC AND LABORATORY TESTING | 737 | ||
| THERAPEUTIC OPTIONS AND CASE MANAGEMENT | 738 | ||
| PROSPECTS OF ERADICATION AND ERADICATION STRATEGIES | 738 | ||
| CHALLENGES AND OPPORTUNITIES | 738 | ||
| REFERENCES | 739 | ||
| Approach to Immunization for the Traveling Child | 745 | ||
| Key points | 745 | ||
| INTRODUCTION | 745 | ||
| IMMUNIZATION PRACTICES | 746 | ||
| ROUTINE IMMUNIZATIONS OF IMPORTANCE FOR TRAVELERS | 746 | ||
| Measles | 746 | ||
| Polio | 747 | ||
| Pertussis | 748 | ||
| Influenza | 748 | ||
| HEALTH PREPARATION FOR LONG-STAY TRAVELERS | 748 | ||
| RECOMMENDED TRAVEL IMMUNIZATIONS | 749 | ||
| Hepatitis A | 749 | ||
| Typhoid Fever | 750 | ||
| Yellow Fever | 751 | ||
| Meningococcal Disease | 752 | ||
| Rabies | 753 | ||
| Japanese Encephalitis | 753 | ||
| TRAVEL VACCINES NOT AVAILABLE IN THE UNITED STATES | 754 | ||
| Bacille Calmette-Guérin | 754 | ||
| Tick-Borne Encephalitis | 755 | ||
| Pediatric Hepatitis A/B Vaccine | 755 | ||
| FUTURE TRAVEL VACCINES | 755 | ||
| REFERENCES | 755 | ||
| Promoting Vaccine Confidence | 759 | ||
| Key points | 759 | ||
| INTRODUCTION | 759 | ||
| WHAT IS VACCINE HESITANCY ANYWAY? | 760 | ||
| HOW COMMON IS VACCINE HESITANCY? | 760 | ||
| COMPLACENCY AND VACCINE RISK PERCEPTIONS | 761 | ||
| CONFIDENCE IN VACCINE SAFETY | 762 | ||
| CONFIDENCE IN THE HEALTH CARE SYSTEM | 762 | ||
| ADDRESSING VACCINE HESITANCY | 764 | ||
| DELIVERING THE MESSAGE | 764 | ||
| STRATEGIES FOR COMMUNICATING WITH VACCINE-HESITANT PARENTS | 765 | ||
| PROLOGUE: BACK TO DISNEY | 766 | ||
| REFERENCES | 768 | ||
| Index | 771 |